These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19366372)

  • 1. Driving in the melanoma landscape.
    Herlyn M
    Exp Dermatol; 2009 Jun; 18(6):506-8. PubMed ID: 19366372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Involvement of matrix metalloproteinases (MMPs) in cutaneous melanoma progression].
    Ntayi C; Hornebeck W; Bernard P
    Pathol Biol (Paris); 2004 Apr; 52(3):154-9. PubMed ID: 15063935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapy for melanoma: current reality and future options.
    Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
    Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
    Lorigan P; Eisen T; Hauschild A
    Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor angiogenesis in melanoma.
    Marneros AG
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic targets in melanoma.
    Martí RM; Sorolla A; Yeramian A
    Actas Dermosifiliogr; 2012 Sep; 103(7):579-90. PubMed ID: 22261672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Lejeune FJ; Rimoldi D; Speiser D
    Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual fronts poised to transform melanoma therapy.
    Mullard A
    Nat Rev Drug Discov; 2011 May; 10(5):325-6. PubMed ID: 21532549
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetics of melanoma tumorigenesis.
    Singh M; Lin J; Hocker TL; Tsao H
    Br J Dermatol; 2008 Jan; 158(1):15-21. PubMed ID: 18047516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma genetics: the other side.
    Bis S; Tsao H
    Clin Dermatol; 2013; 31(2):148-55. PubMed ID: 23438378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular therapeutic approaches to melanoma.
    Ji Z; Flaherty KT; Tsao H
    Mol Aspects Med; 2010 Apr; 31(2):194-204. PubMed ID: 20176049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous melanoma susceptibility and progression genes.
    de Snoo FA; Hayward NK
    Cancer Lett; 2005 Dec; 230(2):153-86. PubMed ID: 16297704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug targeting of oncogenic pathways in melanoma.
    Fecher LA; Amaravadi RK; Schuchter LM; Flaherty KT
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):599-618, x. PubMed ID: 19464605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acquired mutations--basic cancer biology].
    Grønbaek K; Guldberg P
    Ugeskr Laeger; 2006 Jun; 168(24):2335-8. PubMed ID: 16822414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic options in the medical management of advanced melanoma.
    Lutzky J
    Semin Cutan Med Surg; 2010 Dec; 29(4):249-57. PubMed ID: 21277538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma.
    De Stefano I; Raspaglio G; Zannoni GF; Travaglia D; Prisco MG; Mosca M; Ferlini C; Scambia G; Gallo D
    Biochem Pharmacol; 2009 Dec; 78(11):1374-81. PubMed ID: 19643088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
    Matsuoka H; Tsubaki M; Yamazoe Y; Ogaki M; Satou T; Itoh T; Kusunoki T; Nishida S
    Exp Cell Res; 2009 Jul; 315(12):2022-32. PubMed ID: 19393235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.
    Winquist RJ; Boucher DM; Wood M; Furey BF
    Biochem Pharmacol; 2009 Aug; 78(4):326-34. PubMed ID: 19539800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
    Meier F; Guenova E; Clasen S; Eigentler T; Forschner A; Leiter U; Zielinski C; Knaudt B; Garbe C; Berneburg M
    J Am Acad Dermatol; 2009 May; 60(5):863-8. PubMed ID: 19389529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.